144 related articles for article (PubMed ID: 26803356)
1. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus.
Gentile S; Guarino G; Strollo F; Romano M; Genovese S; Masarone M; Ceriello A
Diabetes Res Clin Pract; 2016 Mar; 113():179-86. PubMed ID: 26803356
[TBL] [Abstract][Full Text] [Related]
2. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
4. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
5. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
[TBL] [Abstract][Full Text] [Related]
6. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
[TBL] [Abstract][Full Text] [Related]
7. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
8. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
9. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
[TBL] [Abstract][Full Text] [Related]
10. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
11. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
12. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
[TBL] [Abstract][Full Text] [Related]
13. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
14. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
Anderson JH; Brunelle RL; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
Clin Ther; 1997; 19(1):62-72. PubMed ID: 9083709
[TBL] [Abstract][Full Text] [Related]
15. Humalog (lispro) for type 2 diabetes.
Esposito K; Capuano A; Giugliano D
Expert Opin Biol Ther; 2012 Nov; 12(11):1541-50. PubMed ID: 23043233
[TBL] [Abstract][Full Text] [Related]
16. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia.
Beisswenger PJ; Howell SK; O'Dell RM; Wood ME; Touchette AD; Szwergold BS
Diabetes Care; 2001 Apr; 24(4):726-32. PubMed ID: 11315838
[TBL] [Abstract][Full Text] [Related]
17. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Vaughn DE
Diabetes Care; 2011 Mar; 34(3):666-8. PubMed ID: 21273493
[TBL] [Abstract][Full Text] [Related]
18. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
Burge MR; Waters DL; Holcombe JH; Schade DS
J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
[TBL] [Abstract][Full Text] [Related]
19. Treatment of type 1 diabetes with insulin lispro during Ramadan.
Kadiri A; Al-Nakhi A; El-Ghazali S; Jabbar A; Al Arouj M; Akram J; Wyatt J; Assem A; Ristic S
Diabetes Metab; 2001 Sep; 27(4 Pt 1):482-6. PubMed ID: 11547222
[TBL] [Abstract][Full Text] [Related]
20. Insulin lispro: its role in the treatment of diabetes mellitus.
Campbell RK; Campbell LK; White JR
Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
